1. Scrip
  2. >>Business
  3. >>Earnings

Wegovy Buoys Novo Nordisk To Highest-Ever Sales

 
• By Elizabeth Cairns

But the Danish group is still bedeviled by supply problems, and much is hanging on upcoming cardiovascular outcomes data.  

NovoNordisk

Novo Nordisk A/S is cheerfully setting about destroying its own customer base. Even as the Danish group’s Q3 sales soared by 38% at constant currencies to DKK58.7bn ($8.3bn), its insulin sales contracted, partly because its own Ozempic (semaglutide injection 0.5mg, 1mg, 2mg) means many formerly insulin-dependent diabetes patients no longer need to use the hormone.

Key Takeaways
  • Novo Nordisk reports Q3 sales of $8

The company still cannot meet demand for Ozempic and semaglutide’s other incarnation, Wegovy (semaglutide injection 2.4mg) for obesity, however, and is still unable to say when the situation might ease

More from Earnings

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.